Annual Revenue Comparison: Catalent, Inc. vs Amphastar Pharmaceuticals, Inc.

A Decade of Growth: Catalent, Inc. vs Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Catalent, Inc. and Amphastar Pharmaceuticals, Inc. have shown remarkable trajectories. Catalent, Inc. has consistently outpaced Amphastar, with its revenue growing by approximately 135% from 2014 to 2023. In contrast, Amphastar's revenue increased by about 206% during the same period, showcasing its rapid expansion.

Catalent's revenue peaked in 2022, reaching nearly 4.8 billion, while Amphastar saw its highest revenue in 2023, with a significant jump to 644 million. This data highlights Catalent's steady growth and Amphastar's recent surge. However, 2024 data for Amphastar is missing, leaving room for speculation on its future performance. As these companies continue to innovate, their financial journeys offer valuable insights into the pharmaceutical sector's dynamics.